Cargando…

Country Reports on Practical Aspects of Conducting Large-Scale Community Studies of the Tolerability of Mass Drug Administration with Ivermectin/Diethylcarbamazine/Albendazole for Lymphatic Filariasis

This article is a compilation of summaries prepared by lead investigators for large-scale safety and efficacy studies on mass drug administration of IDA (ivermectin, diethylcarbamazine, and albendazole) for lymphatic filariasis. The summaries highlight the experiences of study teams that assessed th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jambulingam, Purushothaman, Subramanian, Swaminathan, Krishnamoorthy, Kaliannagounder, Supali, Taniawati, Fischer, Peter, Dubray, Christine, Fayette, Carl, Lemoine, Jean Frantz, Laman, Moses, King, Christopher, Samuela, Josaia, Hardy, Myra, Weil, Gary J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Tropical Medicine and Hygiene 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9154653/ https://www.ncbi.nlm.nih.gov/pubmed/35292582 http://dx.doi.org/10.4269/ajtmh.21-0898

Ejemplares similares

An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India
por: Jambulingam, Purushothaman, et al.
Publicado: (2021)

Dosing pole recommendations for lymphatic filariasis elimination: A height-weight quantile regression modeling approach
por: Goss, Charles W., et al.
Publicado: (2019)

An open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. diethylcarbamazine plus albendazole for treatment of brugian filariasis in Indonesia
por: Supali, Taniawati, et al.
Publicado: (2021)

The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study
por: Weil, Gary J., et al.
Publicado: (2019)

Mass drug administration of ivermectin, diethylcarbamazine, plus albendazole compared with diethylcarbamazine plus albendazole for reduction of lymphatic filariasis endemicity in Papua New Guinea: a cluster-randomised trial
por: Laman, Moses, et al.
Publicado: (2022)

Safety and efficacy of co-administered diethylcarbamazine, albendazole and ivermectin during mass drug administration for lymphatic filariasis in Haiti: Results from a two-armed, open-label, cluster-randomized, community study
por: Dubray, Christine L., et al.
Publicado: (2020)

Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa
por: Fischer, Peter U., et al.
Publicado: (2017)

Pharmacokinetics of Moxidectin combined with Albendazole or Albendazole plus Diethylcarbamazine for Bancroftian Filariasis
por: Chhonker, Yashpal S., et al.
Publicado: (2023)

The safety of combined triple drug therapy with ivermectin, diethylcarbamazine and albendazole in the neglected tropical diseases co-endemic setting of Fiji: A cluster randomised trial
por: Hardy, Myra, et al.
Publicado: (2020)

A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis
por: Krentel, Alison, et al.
Publicado: (2021)

Epidemiological Assessment of Eight Rounds of Mass Drug Administration for Lymphatic Filariasis in India: Implications for Monitoring and Evaluation
por: Swaminathan, Subramanian, et al.
Publicado: (2012)

Lessons Learned from the Japanese Encephalitis Vaccine Introduction in India That Supported the Introduction of Ivermectin–Diethylcarbamazine–Albendazole for Lymphatic Filariasis Elimination
por: Ghosh, Raj Shankar, et al.
Publicado: (2022)

Efficacy and Safety of a Single Dose of Ivermectin, Diethylcarbamazine, and Albendazole for Treatment of Lymphatic Filariasis in Côte d’Ivoire: An Open-label Randomized Controlled Trial
por: Bjerum, Catherine M, et al.
Publicado: (2019)

Safety and efficacy of mass drug administration with a single-dose triple-drug regimen of albendazole + diethylcarbamazine + ivermectin for lymphatic filariasis in Papua New Guinea: An open-label, cluster-randomised trial
por: Tavul, Livingstone, et al.
Publicado: (2022)

Safety and Tolerability of Mass Diethylcarbamazine and Albendazole Administration for the Elimination of Lymphatic Filariasis in Kenya: An Active Surveillance Study
por: Khaemba, Christabel, et al.
Publicado: (2021)

Impact of two rounds of mass drug administration using diethylcarbamazine combined with albendazole on the prevalence of Brugia timori and of intestinal helminths on Alor Island, Indonesia
por: Oqueka, Tim, et al.
Publicado: (2005)

Accelerating the Uptake of WHO Recommendations for Mass Drug Administration Using Ivermectin, Diethylcarbamazine, and Albendazole
por: King, Jonathan D., et al.
Publicado: (2022)

The Impact of Repeated Rounds of Mass Drug Administration with Diethylcarbamazine Plus Albendazole on Bancroftian Filariasis in Papua New Guinea
por: Weil, Gary J., et al.
Publicado: (2008)

Diethylcarbamazine citrate-fortified salt for lymphatic filariasis elimination in India
por: Sabesan, S., et al.
Publicado: (2022)

Molecular xenomonitoring as a post-MDA surveillance tool for global programme to eliminate lymphatic filariasis: Field validation in an evaluation unit in India
por: Subramanian, Swaminathan, et al.
Publicado: (2020)

A randomized, open-label study of the tolerability and efficacy of one or three daily doses of ivermectin plus diethylcarbamazine and albendazole (IDA) versus one dose of ivermectin plus albendazole (IA) for treatment of onchocerciasis
por: Opoku, Nicholas O., et al.
Publicado: (2023)

Mathematical models for lymphatic filariasis transmission and control: Challenges and prospects
por: Swaminathan, Subramanian, et al.
Publicado: (2008)

Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without Wuchereria bancrofti infection in Côte d’Ivoire
por: Edi, Constant, et al.
Publicado: (2019)

Application of a household-based molecular xenomonitoring strategy to evaluate the lymphatic filariasis elimination program in Tamil Nadu, India
por: Subramanian, Swaminathan, et al.
Publicado: (2017)

Lymphatic Filariasis Control in Tanzania: Effect of Repeated Mass Drug Administration with Ivermectin and Albendazole on Infection and Transmission
por: Simonsen, Paul E., et al.
Publicado: (2010)

Prevalence of Lymphatic Filariasis and Treatment Effectiveness of Albendazole/ Ivermectin in Individuals with HIV Co-infection in Southwest-Tanzania
por: Kroidl, Inge, et al.
Publicado: (2016)

Recurrent Hemorrhagic Pericardial Effusion and Tamponade due to Filariasis Successfully Treated with Ivermectin and Albendazole
por: Sinha, Santosh Kumar, et al.
Publicado: (2015)

Lymphatic filariasis control in Tanzania: effect of six rounds of mass drug administration with ivermectin and albendazole on infection and transmission
por: Simonsen, Paul E, et al.
Publicado: (2013)

Correction: Prevalence of Lymphatic Filariasis and Treatment Effectiveness of Albendazole/ Ivermectin in Individuals with HIV Co-infection in Southwest-Tanzania
por: Kroidl, Inge, et al.
Publicado: (2016)

Mapping and monitoring for a lymphatic filariasis elimination program: a systematic review
por: Srividya, Adinarayanan, et al.
Publicado: (2019)

A Retrospective Study of the Efficacy of Albendazole and Diethylcarbamazine for the Treatment of Human Toxocariasis
por: Magnaval, Jean-François, et al.
Publicado: (2022)

Filariasis Control with Diethylcarbamazine in Three Major Endemic Areas in Japan
por: Tada, Isao
Publicado: (2011)

Molecular xenomonitoring of diurnally subperiodic Wuchereria bancrofti infection in Aedes (Downsiomyia) niveus (Ludlow, 1903) after nine rounds of Mass Drug Administration in Nancowry Islands, Andaman and Nicobar Islands, India
por: Premkumar, Addepalli, et al.
Publicado: (2020)

Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis
por: Macfarlane, Cara L, et al.
Publicado: (2019)

Treatment of co-infection with bancroftian filariasis and onchocerciasis: a safety and efficacy study of albendazole with ivermectin compared to treatment of single infection with bancroftian filariasis
por: Makunde, William H, et al.
Publicado: (2003)

Prevalence and Correlates of Lymphatic Filariasis Infection and Its Morbidity Following Mass Ivermectin and Albendazole Administration in Mkinga District, North-Eastern Tanzania
por: Fimbo, Adam M., et al.
Publicado: (2020)

Safety and Tolerability of Ivermectin and Albendazole Mass Drug Administration in Lymphatic Filariasis Endemic Communities of Tanzania: A Cohort Event Monitoring Study
por: Fimbo, Adam M., et al.
Publicado: (2022)

Evaluation of Lymphatic Filariasis and Onchocerciasis in Three Senegalese Districts Treated for Onchocerciasis with Ivermectin
por: Wilson, Nana O., et al.
Publicado: (2016)

Comparison of the Impact of Annual and Semiannual Mass Drug Administration on Lymphatic Filariasis Prevalence in Flores Island, Indonesia
por: Supali, Taniawati, et al.
Publicado: (2019)

Mathematical modelling of lymphatic filariasis elimination programmes in India: required duration of mass drug administration and post-treatment level of infection indicators
por: Jambulingam, Purushothaman, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_qdq1f7226tinsmdlm18p9pl3ug